Oncoheroes Biosciences 9/3/24 Oncoheroes Biosciences 9/3/24 Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib Read More Oncoheroes Biosciences 10/13/23 Oncoheroes Biosciences 10/13/23 Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More Oncoheroes Biosciences 10/2/23 Oncoheroes Biosciences 10/2/23 FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials Read More Oncoheroes Biosciences 9/22/22 Oncoheroes Biosciences 9/22/22 FDA Grants Rare Pediatric Disease Designation (RPDD) to dovitinib for osteosarcoma Read More partnership Oncoheroes Biosciences 7/14/22 partnership Oncoheroes Biosciences 7/14/22 Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas Read More Oncoheroes Biosciences 1/3/22 Oncoheroes Biosciences 1/3/22 Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib Read More Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy Read More Oncoheroes Biosciences 2/15/21 Oncoheroes Biosciences 2/15/21 SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers Read More Oncoheroes Biosciences 10/14/20 Oncoheroes Biosciences 10/14/20 Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More Oncoheroes Biosciences 9/24/20 Oncoheroes Biosciences 9/24/20 FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma Read More
Oncoheroes Biosciences 9/3/24 Oncoheroes Biosciences 9/3/24 Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib Read More
Oncoheroes Biosciences 10/13/23 Oncoheroes Biosciences 10/13/23 Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More
Oncoheroes Biosciences 10/2/23 Oncoheroes Biosciences 10/2/23 FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials Read More
Oncoheroes Biosciences 9/22/22 Oncoheroes Biosciences 9/22/22 FDA Grants Rare Pediatric Disease Designation (RPDD) to dovitinib for osteosarcoma Read More
partnership Oncoheroes Biosciences 7/14/22 partnership Oncoheroes Biosciences 7/14/22 Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas Read More
Oncoheroes Biosciences 1/3/22 Oncoheroes Biosciences 1/3/22 Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib Read More
Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences 11/11/21 Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy Read More
Oncoheroes Biosciences 2/15/21 Oncoheroes Biosciences 2/15/21 SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers Read More
Oncoheroes Biosciences 10/14/20 Oncoheroes Biosciences 10/14/20 Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA Read More
Oncoheroes Biosciences 9/24/20 Oncoheroes Biosciences 9/24/20 FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma Read More
